Status:
RECRUITING
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Lead Sponsor:
Astellas Pharma Korea, Inc.
Collaborating Sponsors:
Seagen Inc.
Conditions:
Urothelial Cancer
Eligibility:
All Genders
Brief Summary
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer. People in this study will be adul...
Eligibility Criteria
Inclusion
- Patients who receive treatment with PADCEV Injection, according to the approved local label.
Exclusion
- Patients with any contraindication for PADCEV Injection, according to the approved local label.
- Patients who receive or are going to receive any investigational medicine during the observation period.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT06011954
Start Date
November 1 2023
End Date
July 31 2027
Last Update
December 11 2025
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Site KR82001
Goyang-si, Gyeonggi-do, South Korea, 10408
2
Site KR82012
Suwon, Gyeonggi-do, South Korea, 16247
3
Site KR82008
Suwon, Gyeonggi-do, South Korea, 16500
4
Site KR82007
Jeollanam-do, Jeollanam-do, South Korea, 58128